TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Return to Play
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percent Change in Bone Mineral Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Serum 25(OH)D Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Change From Baseline in Total Lesion Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression Symptoms Over Time
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HIV-Related Medication Adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Pain scores at rest and motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics (Area Under the Curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive performance on Cambridge Cognition tests (CANTAB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in height-for-age z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional muscle ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Localized change in pulmonary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Probability of collapse of peripheral BSS segments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Concentration of Posaconazole on Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Concentration of Posaconazole on Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transcriptional changes in plasma LPS levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eating episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of BK viremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: duration of the somatosensory evoked potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Catheter tip microbial colonization
Endpoint domain: Adverse events/effects
Primary endpoint: Leakage Under the Base Plate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting Triglycerides levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PANSS Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SANS Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MATRICS Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical agreement between EUA RT-PCR and Nanomix eLab® COVID-19 Rapid Antigen Panel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weighted Mean Glucose Change From Baseline at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GLP-1 AUEC Change From Baseline at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Smartphone Addiction Scale-Short
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: International Physical Activity Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mental health service use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: maximum oxygen uptake (peak VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite endpoint of mortality and heart failure events
Endpoint domain: Mortality/survival
Primary endpoint: Emergency visits for heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Knowledge about EbM/GSP
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Efficacy of nitrous oxide compared to placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of obstetric anal sphincter injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Kansas City Cardiomyopathy Questionnaire (KCCQ) change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Vitreous haze
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to prostate-specific antigen (PSA) and objective progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response rate (PSA and objective)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Hamilton Depressive Rating Scale (HDRS-17)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Heart rate at two minutes of life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a 50% or Greater Reduction in Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Lumen Clot Formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Catheter Related Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Malfunction
Endpoint domain: Adverse events/effects
Primary endpoint: Time to appearance of reinjection criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spasticity symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood ketones level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total amount of sera withdrawn from the wound cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in MRI BOLD signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective and behavioral task report
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in BC habits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to complete BC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reductions/increases in secondary methods needed to complete BC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax/MIC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of incidence of nosocomial MRSA acquisition
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Atrial Fibrillation Detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline Canadian Occupational Performance Measure-Chinese version (COPM-C)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cumulative Individual Irritation Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety Outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Level of Antibody Titers in Serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Level of Antibody Titers in Stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Triglyceride-rich lipoprotein apolipoprotein B100 production rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants with DVT excluded
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with correct diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Success (Marked Improvement or Completely Cleared)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacteriological Success (Eradication)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence, Severity, and Duration of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Method of Resolution of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: ketamine-induced positive psychotic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mycological Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Survival Probability
Endpoint domain: Mortality/survival
Primary endpoint: cerebral blood volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: contrast agent extravasation rate constant (Ktrans, 1/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeatability coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in arsenic methylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in blood arsenic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in blood monomethyl arsenic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Niacin Induced Flushing (NIF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical point accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of diabetic neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Parasite Clearance Times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention in MAT
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Relapse to drug use
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnosis of RDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Scale of Prodromal Symptoms (SOPS) Negative Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Experienced a Clinical Exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the 7-Day Average Daily Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients attaining remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of changes after procedure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: expression levels of biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Nerve Conduction Studies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Nausea 1 Hour After PACU Admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of Nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in High-Density Lipoprotein (HDL) Particle Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Change in Low-Density Lipoprotein (LDL) Particle Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Change in Very Low-Density Lipoprotein (VLDL) Particle Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Telephone Modified Rankin Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macrophage function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Near-infrared spectroscopy during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Exercise test with hand held dynamometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarkers of platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mirtazapine response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implants survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Hospital admission for COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Intensive unit care because of a diagnosis of COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Death for COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Overall Proportion Saying Yes to Real Prism Glasses
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical diagnosis of MCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical diagnosis of AD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment success rate at week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Forced Expiratory Volume in first second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of Incidental Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total dose administered during breast irradiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum tolerated dose of RAD001
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average subjective Sleep Latency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: self-reported hunger and fullness rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: abnormalities of compulsive behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional activation of ventral fronto-striatal systems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with dose limited toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Time To Progression (TTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of successful colonoscopies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Virological relapse occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective self report pain assessment after anesthesia and extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological record of pain after anesthesia and extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Blood gases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall survival (OS) at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: levels of cathelicidin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: clinical efficacy of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Analyte Concentration Versus Time Curve (AUC [0-72 hours])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Analyte Concentration Versus Time Curve (AUC [0-408 hours])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Analyte Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen level in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of mtDNA concentration in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Report 1 or More Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Were Discontinued From the Study Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in plasma Interleukin-6 status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Systemic clearance of acetaminophen and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With One or More Composite Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients who require rescue analgesic
Endpoint domain: Adverse events/effects
Primary endpoint: The average pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting at Least One NRS Rating
Endpoint domain: Adverse events/effects
Primary endpoint: 2 Minutes Walking Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Olerud-Molander score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Postoperative hypocalcemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sore throat severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Potentially avoidable readmission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants with adverse events (AEs) in Part 1
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with laboratory value abnormalities and/or AEs in Part 1
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with vital sign abnormalities and/or AEs in Part 1
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with electrocardiogram (ECG) abnormalities and/or AEs in Part 1
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with AEs in Part 2
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum drug concentration versus time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum drug concentration (Cmax) and minimal drug concentration (Cmin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Enrolled participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of extra ocular relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in numeric rating scale (NRS) at 3 months after the procedure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Oswestry disability index (ODI) at 3 months after the procedure
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Global perceived effect (GPE) score at 3 months after the procedure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Identification of antibodies against cetuximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean number of patients with acute urinary retention and/or prostate surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum-tolerated dose of lenalidomide with cetuximab
Endpoint domain: Adverse events/effects
Primary endpoint: Change in menstrual pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average accuracy of tissue thickness measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mortality (in ICU and in the hospital)
Endpoint domain: Mortality/survival
Primary endpoint: rate of additional antibiotherapy course
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of malapposed and uncovered stent strut
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Social disruption
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Cumulative number of new or enlarging Gd+ lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Abnormal laboratory changes
Endpoint domain: Adverse events/effects
Primary endpoint: Hypolipidemic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Liver function tests
Endpoint domain: Adverse events/effects
Primary endpoint: Physiological effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Minimal tolerated length of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Brief-A Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Chronic kidney disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Therapeutic Alliance score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status